Genprex Inc (NASDAQ:GNPX)’s share price traded up 6% on Monday . The stock traded as high as $3.87 and last traded at $3.71. 804,383 shares were traded during mid-day trading, a decline of 81% from the average session volume of 4,222,872 shares. The stock had previously closed at $3.50.
Several research analysts recently weighed in on the stock. Noble Financial reaffirmed a “buy” rating and issued a $5.00 target price on shares of Genprex in a report on Tuesday, May 26th. ValuEngine downgraded shares of Genprex from a “buy” rating to a “hold” rating in a report on Thursday, July 2nd.
The firm’s fifty day simple moving average is $3.77 and its 200 day simple moving average is $3.12. The firm has a market cap of $146.93 million, a P/E ratio of -6.26 and a beta of -0.81.
Genprex (NASDAQ:GNPX) last released its quarterly earnings data on Tuesday, August 11th. The company reported ($0.12) EPS for the quarter, beating the consensus estimate of ($0.19) by $0.07. Equities analysts predict that Genprex Inc will post -0.47 EPS for the current year.
Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Mid Atlantic Financial Management Inc. ADV purchased a new stake in shares of Genprex during the 1st quarter valued at about $38,000. Bank of New York Mellon Corp purchased a new stake in shares of Genprex during the 1st quarter valued at about $60,000. Virtu Financial LLC purchased a new stake in shares of Genprex during the 2nd quarter valued at about $96,000. Advisor Group Holdings Inc. purchased a new stake in shares of Genprex during the 1st quarter valued at about $159,000. Finally, New York State Common Retirement Fund purchased a new stake in shares of Genprex during the 2nd quarter valued at about $90,000. 13.05% of the stock is owned by institutional investors and hedge funds.
Genprex Company Profile (NASDAQ:GNPX)
Genprex, Inc operates as a clinical-stage gene therapy company. It engages in developing a new approach for treating cancer based on its novel proprietary technology platform, including initial product candidate, Oncoprex immunogene therapy. Oncoprex, which has a multimodal mechanism of action whereby it interrupts cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for apoptosis in cancer cells, and modulates the immune response against cancer cells.
Further Reading: Economic Reports
Receive News & Ratings for Genprex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genprex and related companies with MarketBeat.com's FREE daily email newsletter.